Loading…
← CockpitCompetitor Analysis › 3696.HK InSilico Medicine Cayman TopCoOpen in the cockpit ↗

InSilico Medicine Cayman TopCo3696.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major

AI-driven drug-discovery company using generative AI (Pharma.AI) to design new drug candidates.

≈ A Chinese/global Recursion Pharmaceuticals-style AI drug-discovery biotechMomentum weak 35
Mkt cap
$2.40B
US dollars, full cap
Free float
83%
of shares outstanding
$/day
$48.4M
20-day average traded
Fwd P/E
85.2×
forward earnings
ROIC−WACC
n/a
WACC 17.3%
Hurdle
+15 pp
Req g minus delivered
Next earnings
131 days
29 Mar 2027
Close · HKDHK$34.62
1D+1.4%
1W-12.3%
1M-12.2%
3M-12.2%
6M-32.9%
YTD-6.8%
1Yn/a
ATR %8.1%
52w lowhigh57.2% off high

What InSilico Medicine Cayman TopCo does

AI-driven drug-discovery company using generative AI (Pharma.AI) to design new drug candidates.

Earns from licensing and collaboration deals, where drug companies pay upfront and milestone amounts when a candidate it designed is handed over or reaches a stage, plus fees for access to its software, so revenue is uneven. Its own drug pipeline absorbs most spending.

In one line: A Chinese/global Recursion Pharmaceuticals-style AI drug-discovery biotech.

Products and services

  • Pharma.AI discovery platform
  • In-house drug pipeline (fibrosis, oncology)
  • Software licensing to pharma partners

Customers

  • Pharma partners (licensing/collaboration deals)
  • Hospitals (post-approval)

Where it sits in the supply chain

  • Biotechnology
  • AI-driven drug discovery
  • Clinical-stage pipeline

What could go right

  • Pharma partnership/licensing deals
  • AI drug-discovery adoption

What could go wrong

  • Clinical trial failure risk
  • Heavy cash burn pre-revenue

Moat: narrow (IP / patents, data, process know-how). Proprietary generative-AI models trained on large biological/chemical datasets.

Headquarters: Hong Kong / Cayman Islands · Founded: 2014 · Employees: 317

Named competitors

InSilico Medicine Cayman TopCo at a glance

Size InSilico Medicine Cayman TopCo (3696.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $2.40B, the 373rd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$34.62 on 18 Nov 2026.

Performance Over six months the shares fell 32.9%, against -9.7% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 4th lowest of 21 in its peer set.

Growth Revenue grew 153.0% over the last twelve months (peer median +4.2%); the operating margin is -6.8% (peer median 10.6%).

Valuation It trades at 85.2× forward earnings against a peer median of 26.2× (most expensive of 15).

Price implies For today's price to make sense, revenue must grow about 38% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is +15 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 893696.HK 72
Six months, rebased to 100: InSilico Medicine Cayman TopCo against the median of its 20 peers (local-currency closes).

InSilico Medicine Cayman TopCo financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$1.06BHK$438MHK$670MHK$401MHK$236M
Revenue growth—-35%+67%+70%—
Gross profitHK$929MHK$357MHK$605MHK$302MHK$150M
EBITDA-HK$32.8M-HK$430M-HK$244M-HK$620M-HK$613M
Net income-HK$2.32B-HK$2.75B-HK$133M-HK$1.66B-HK$1.74B
Free cash flowHK$342M-HK$578M-HK$395M-HK$232M-HK$457M
Capital expenditureHK$22.9MHK$23.2MHK$7.22MHK$23.3MHK$87.9M
Total debtn/aHK$46.4MHK$19.9MHK$17.1MHK$25.2M

Quarterly statements and history in the cockpit →

InSilico Medicine Cayman TopCo competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%2162PBH0013NAMS000250PRGOALMRGC301080301301603858IDYA600518APLLTD600267BIOA-B3001993696.HK6-month return →1-month return →
Up and to the right = strong over both horizons. InSilico Medicine Cayman TopCo is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%+150%25×50×75×2162PBH0013PRGOALM301080301301600267BIOA-B3001993005582144503696.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. InSilico Medicine Cayman TopCo is the large dot.

Capital: growth delivered against growth the price implies

0%+25%+50%+75%+100%0%50%100%PBH0013PRGOALM301080603858APLLTD600867600267BIOA-B3001993005582144503696.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. InSilico Medicine Cayman TopCo is the large dot.

InSilico Medicine Cayman TopCo competitors and peer comparison

Head to head with its named competitors (3696.HK vs RXRX vs SDGR vs 2228.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
InSilico Medicine Cayman TopCo 3696.HK$2.40B-33%+153%-7%85.2×37.9%
Recursion Pharmaceuticals RXRX$1.76B-5%+56%-725%n/an/a
Schrodinger SDGR$2.04B+127%+5%-50%n/an/a
XtalPi 2228.HK$2.87B-34%+4%-127%n/an/a

How InSilico Medicine Cayman TopCo compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

InSilico Medicine Cayman TopCo against its 20 peers (data as of 18 Nov 2026)
Measure3696.HKPeer medianRank in peer set
1-month return-12.2%-3.1%7th lowest of 21
6-month return-32.9%-9.7%4th lowest of 21
Distance from 52-week high-57.2%-28.5%3rd lowest of 21
Revenue growth (TTM)+153.0%+4.2%highest of 20
Operating margin-6.8%10.6%4th lowest of 19
Forward P/E85.2×26.2×most expensive of 15
Growth the price implies (Req g, 7 yrs)37.9%10.1%3rd most demanding of 15
Growth delivered (Del g)+22.9%+6.3%4th highest of 15
Hurdle (Req g minus delivered)+15.0 pp+1.9 pp4th most demanding of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
InSilico Medicine Cayman TopCo 3696.HKHong Kong$2.40B-33%+153%-7%85.2×37.9%+22.9%
Keymed Biosciences 2162.HKHong Kong$2.39B+7%0%-73%18.2×n/an/a
Prestige Consumer Healthcare PBHUnited States$2.40B+7%+5%25%10.6×2.3%+2.9%
HUTCHMED (China) 0013.HKHong Kong$2.38B+14%-9%-6%35.9×47.0%+19.3%
NewAmsterdam Pharma NAMSUnited States$2.37B-45%-26%-900%n/an/an/a
Sam Chun Dang Pharm 000250.KSSouth Korea$2.36B-66%+23%7%n/an/an/a
Perrigo PRGOUnited States$2.35B+52%-4%5%6.7×14.1%+0.8%
Almirall ALM.MCSpain$2.46B-13%+24%8%27.1×6.1%+6.5%
Regencell Bioscience RGCUnited States$2.33B-83%n/an/an/an/an/a
Acrobiosystems 301080.SZChina$2.31B+65%+29%17%55.2×41.3%+27.7%
Yili Chuanning Biotechnology 301301.SZChina$2.49B-24%-14%16%27.6×3.4%+4.8%
Shandong Buchang Pharmaceuticals 603858.SSChina$2.25B-7%+4%10%n/a-2.5%-5.8%
IDEAYA Biosciences IDYAUnited States$2.56B-11%-83%-1,267%n/an/an/a
Kangmei Pharmaceutical 600518.SSChina$2.61B-21%-6%-7%n/an/an/a
Alembic Pharmaceuticals APLLTD.NSIndia$2.20B+39%+20%12%25.0×26.7%+6.5%
Tonghua Dongbao Pharmaceutical 600867.SSChina$2.19B-12%+18%n/a25.4×0.9%+0.3%
Zhejiang Hisun Pharmaceutical 600267.SSChina$2.19B+14%-7%15%15.0×-9.7%-1.5%
BioArctic BIOA-B.STSweden$2.66B-9%-46%22%52.9×25.5%+100.1%
Hybio Pharmaceutical 300199.SZChina$2.68B-8%+70%31%44.7×37.4%+6.1%
Betta Pharmaceuticals 300558.SZChina$2.70B-15%+16%11%38.0×23.2%+14.0%
PharmaResearch 214450.KSSouth Korea$2.10B-24%+29%37%15.4×-11.0%+37.6%

Questions

Who are InSilico Medicine Cayman TopCo's main competitors?
Named competitors: Recursion Pharmaceuticals (RXRX), Schrodinger (SDGR), XtalPi (2228.HK), BenevolentAI (private or unlisted). The cockpit's measured peer set (industry) also includes Keymed Biosciences (2162.HK), Prestige Consumer Healthcare (PBH), HUTCHMED (China) (0013.HK), NewAmsterdam Pharma (NAMS), Sam Chun Dang Pharm (000250.KS), Perrigo (PRGO).
Is InSilico Medicine Cayman TopCo expensive compared with its peers?
On forward p/e it trades at 85.2× against a peer median of 26.2×, most expensive of 15 in its peer set. For today's price to make sense, revenue must grow about 38% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is +15 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has InSilico Medicine Cayman TopCo stock performed?
Over six months to 18 Nov 2026 the shares returned -32.9% against -9.7% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.